Literature DB >> 30266608

Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial.

Thomas J Ford1, Bethany Stanley2, Richard Good3, Paul Rocchiccioli4, Margaret McEntegart4, Stuart Watkins3, Hany Eteiba3, Aadil Shaukat3, Mitchell Lindsay3, Keith Robertson3, Stuart Hood3, Ross McGeoch5, Robert McDade3, Eric Yii6, Novalia Sidik6, Peter McCartney6, David Corcoran6, Damien Collison4, Christopher Rush6, Alex McConnachie2, Rhian M Touyz6, Keith G Oldroyd4, Colin Berry7.   

Abstract

BACKGROUND: Patients with angina symptoms and/or signs of ischemia but no obstructive coronary artery disease (INOCA) pose a diagnostic and therapeutic challenge.
OBJECTIVES: The purpose of this study was to test whether an interventional diagnostic procedure (IDP) linked to stratified medicine improves health status in patients with INOCA.
METHODS: The authors conducted a randomized, controlled, blinded clinical trial of stratified medical therapy versus standard care in patients with angina. Patients with angina undergoing invasive coronary angiography (standard care) were recruited. Patients without obstructive CAD were immediately randomized 1:1 to the intervention group (stratified medical therapy) or the control group (standard care, IDP sham procedure). The IDP consisted of guidewire-based assessment of coronary flow reserve, index of microcirculatory resistance, fractional flow reserve, followed by vasoreactivity testing with acetylcholine. The primary endpoint was the mean difference in angina severity at 6 months (assessed by the Seattle Angina Questionnaire summary score).
RESULTS: A total of 391 patients were enrolled between November 25, 2016, and November 12, 2017. Coronary angiography revealed obstructive disease in 206 (53.7%). One hundred fifty-one (39%) patients without angiographically obstructive CAD were randomized (n = 76 intervention group; n = 75 blinded control group). The intervention resulted in a mean improvement of 11.7 U in the Seattle Angina Questionnaire summary score at 6 months (95% confidence interval [CI]: 5.0 to 18.4; p = 0.001). In addition, the intervention led to improvements in the mean quality-of-life score (EQ-5D index 0.10 U; 95% CI: 0.01 to 0.18; p = 0.024) and visual analogue score (14.5 U; 95% CI: 7.8 to 21.3; p < 0.001). There were no differences in major adverse cardiac events at the 6-month follow-up (2.6% controls vs. 2.6% intervention; p = 1.00).
CONCLUSIONS: Coronary angiography often fails to identify patients with vasospastic and/or microvascular angina. Stratified medical therapy, including an IDP with linked medical therapy, is routinely feasible and improves angina in patients with no obstructive CAD. (CORonary MICrovascular Angina [CorMicA]; NCT03193294).
Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  INOCA; elective coronary angiography; microvascular angina; stable angina pectoris; stratified medical therapy; vasospastic angina

Mesh:

Year:  2018        PMID: 30266608     DOI: 10.1016/j.jacc.2018.09.006

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  96 in total

1.  A further explanation for chest pain without visible coronary artery disease.

Authors:  Tom Newman; Paul Morris; Julian Gunn
Journal:  Clin Med (Lond)       Date:  2021-03       Impact factor: 2.659

2.  Coronary microvascular disease: the next frontier for Cardiovascular Research.

Authors:  Colin Berry; Dirk J Duncker
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 10.787

3.  An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group.

Authors:  Vijay Kunadian; Alaide Chieffo; Paolo G Camici; Colin Berry; Javier Escaned; Angela H E M Maas; Eva Prescott; Nicole Karam; Yolande Appelman; Chiara Fraccaro; Gill Louise Buchanan; Stephane Manzo-Silberman; Rasha Al-Lamee; Evelyn Regar; Alexandra Lansky; J Dawn Abbott; Lina Badimon; Dirk J Duncker; Roxana Mehran; Davide Capodanno; Andreas Baumbach
Journal:  Eur Heart J       Date:  2020-10-01       Impact factor: 29.983

Review 4.  Microvascular Angina Diagnosed by Absolute PET Myocardial Blood Flow Quantification.

Authors:  Matthieu Pelletier-Galarneau; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2020-01-28       Impact factor: 2.931

Review 5.  Coronary Arterial Function and Disease in Women With No Obstructive Coronary Arteries.

Authors:  Harmony R Reynolds; C Noel Bairey Merz; Colin Berry; Rohit Samuel; Jacqueline Saw; Nathaniel R Smilowitz; Ana Carolina do A H de Souza; Robert Sykes; Viviany R Taqueti; Janet Wei
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 17.367

Review 6.  Management of Angina Post Percutaneous Coronary Intervention.

Authors:  Jose B Cruz Rodriguez; Subrata Kar
Journal:  Curr Cardiol Rep       Date:  2020-01-21       Impact factor: 2.931

Review 7.  Coronary Microvascular Dysfunction: A Practical Approach to Diagnosis and Management.

Authors:  Daria Frestad Bechsgaard; Eva Prescott
Journal:  Curr Atheroscler Rep       Date:  2021-07-16       Impact factor: 5.113

Review 8.  Syndrome of Nonobstructive Coronary Artery Diseases: A Comprehensive Overview of Open Artery Ischemia.

Authors:  Lina Ya'qoub; Islam Y Elgendy; Carl J Pepine
Journal:  Am J Med       Date:  2021-07-31       Impact factor: 4.965

Review 9.  Angiogenic CD34 Stem Cell Therapy in Coronary Microvascular Repair-A Systematic Review.

Authors:  Balaj Rai; Janki Shukla; Timothy D Henry; Odayme Quesada
Journal:  Cells       Date:  2021-05-08       Impact factor: 7.666

10.  A novel method for measuring absolute coronary blood flow and microvascular resistance in patients with ischaemic heart disease.

Authors:  Paul D Morris; Rebecca Gosling; Iwona Zwierzak; Holli Evans; Louise Aubiniere-Robb; Krzysztof Czechowicz; Paul C Evans; D Rodney Hose; Patricia V Lawford; Andrew J Narracott; Julian P Gunn
Journal:  Cardiovasc Res       Date:  2021-05-25       Impact factor: 13.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.